TY - JOUR
T1 - Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer
AU - Goldstein, David
AU - Von Hoff, Daniel D.
AU - Chiorean, E. Gabriela
AU - Reni, Michele
AU - Tabernero, Josep
AU - Ramanathan, Ramesh K.
AU - Botteman, Marc
AU - Aly, Abdalla
AU - Margunato-Debay, Sandra
AU - Lu, Brian
AU - Louis, Chrystal U.
AU - McGovern, Desmond
AU - Lee, Chee Khoon
N1 - Publisher Copyright:
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Objectives This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. Methods Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P < 0.1) were selected to generate the primary nomogram, which was internally validated using bootstrapping, a concordance index, and calibration plots. Results Using data from 861 patients, 6 factors were retained (multivariable analysis): Neutrophil-lymphocyte ratio, albumin level, Karnofsky performance status, sum of longest diameter of target lesions, presence of liver metastases, and previous Whipple procedure. The nomogram distinguished low-, medium-, and high-risk groups (concordance index, 0.67; 95% confidence interval, 0.65-0.69; median OS, 11.7, 8.0, and 3.3 months, respectively). Conclusions This nomogram may guide estimates of the range of OS outcomes and contribute to patient stratification in future prospective metastatic pancreatic cancer trials; however, external validation is required to improve estimate reliability and applicability to a general patient population. Caution should be exercised in interpreting these results for treatment decisions: Patient characteristics could differ from those included in the nomogram development.
AB - Objectives This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. Methods Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P < 0.1) were selected to generate the primary nomogram, which was internally validated using bootstrapping, a concordance index, and calibration plots. Results Using data from 861 patients, 6 factors were retained (multivariable analysis): Neutrophil-lymphocyte ratio, albumin level, Karnofsky performance status, sum of longest diameter of target lesions, presence of liver metastases, and previous Whipple procedure. The nomogram distinguished low-, medium-, and high-risk groups (concordance index, 0.67; 95% confidence interval, 0.65-0.69; median OS, 11.7, 8.0, and 3.3 months, respectively). Conclusions This nomogram may guide estimates of the range of OS outcomes and contribute to patient stratification in future prospective metastatic pancreatic cancer trials; however, external validation is required to improve estimate reliability and applicability to a general patient population. Caution should be exercised in interpreting these results for treatment decisions: Patient characteristics could differ from those included in the nomogram development.
KW - clinical variables
KW - metastatic pancreatic cancer
KW - nab-paclitaxel plus gemcitabine
KW - nomogram
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85087126173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087126173&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001563
DO - 10.1097/MPA.0000000000001563
M3 - Article
C2 - 32541630
AN - SCOPUS:85087126173
SN - 0885-3177
VL - 49
SP - 744
EP - 750
JO - Pancreas
JF - Pancreas
IS - 6
ER -